Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-02-02
1996-01-30
Sayala, Chhaya D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 21, 530350, A61K 3514, A61K 3816
Patent
active
054880343
ABSTRACT:
Bactericidal/permeability increasing (BPI) polypeptide pharmaceutical compositions having improved stability and resistance to aggregation, particle formation and precipitation comprising the polypeptide pharmaceutical and poloxamer surfactants alone, or in combination with polysorbate suractants. Preferred BPI polypeptides stabilized are bactericidal/permeability increasing (BPI) protein, biologically active fragments of BPI, and biologically active analogs of BPI.
REFERENCES:
patent: 3839314 (1974-10-01), Fekete et al.
patent: 4478829 (1984-10-01), Landaburu et al.
patent: 4719239 (1988-01-01), Muller et al.
patent: 4933179 (1990-06-01), Allison et al.
patent: 5030448 (1991-07-01), Hunter
patent: 5037664 (1991-08-01), Shaked et al.
patent: 5039520 (1991-08-01), Hunter
patent: 5041288 (1991-08-01), Hunter
patent: 5071649 (1991-12-01), Hunter
patent: 5096885 (1992-03-01), Pearlman et al.
patent: 5118528 (1992-06-01), Fessi et al.
patent: 5118794 (1992-06-01), Grangeorge et al.
patent: 5133908 (1992-07-01), Stainmesse et al.
patent: 5152979 (1992-10-01), Hunter
patent: 5182106 (1993-01-01), Mezrow et al.
patent: 5234683 (1993-08-01), Hunter et al.
patent: 5234908 (1993-08-01), Szabo et al.
patent: 5234912 (1993-08-01), Marra et al.
Wang et al., Jour. of Parenteral Sci. & Tech, vol. 42, No. 2S, pp. S1-S26, 1988.
FDA, Division of Drug Information Resources, "Inactive Ingredient Guide" including list of Currently Marketed Injectable Products, (1991).
FDA review and basis for approval of OB-NDA-86-0909 on FLUOSOL.RTM. (20% Intravascular Perflorochemical Emulsion), The Green Cross Corp. (1989).
Genentech, Inc., "A Tissue Plasminogen Activator," Product Information (1987).
Gray et al., "Cloning of the cDNA of a Human Neutrophil Bactericidal Protein," J. Biol. Chem., 264(16):9505-9509 (Jun. 5, 1989).
The Green Cross Corporation, "Perfluorochemical Blood Substitutes," Technical Info. Series Nos. 5 & 7 (1978 and 1981).
Henson et al., "The Surface Coagulation of Proteins During Shaking," J. Colloid & Interface Sci., 32(1):162-165 (Jan. 1970).
ICI Americas, Inc., "ICI Americas Products For Cosmetics and Pharmaceuticals," Chapters 1-4, pp. 1-39 (1977).
ICI Americas, Inc., "The HLB System," Chapters 1-8, pp. 3-20 (1984).
Kaplan and Fraser, "Formation of Fibres from Protein Monolayers," Nature, 171(4352):559-560 (Mar. 28, 1953).
Krantz et al., "Sugar Alcohols," Bulletin of School of Medicine, U. of MD, 36:48-56 (1951).
Levine et al., "The Use of Surface Tension Measurements in the Design of Antibody-Based Product Formulations," J. Parenteral Sci. & Tech., 45(3):160-165 (May-Jun. 1991).
MacRitchie, "Proteins at Interfaces," Adv. Protein Chem., 32:283-326 (1978).
Neugebauer, "A Guide to the Properties and Uses of Detergents in Biology and Biochemistry," Calbiochem.RTM. Brand Chemicals, Hoechst Celanese Corp. (1987).
ORTHO Pharmaceutical Corporation, "Orthocolone OKT-3," Product Information Package Insert (1986).
The U.S. Pharmacopeia USPXXII, pp. 1763, 1857, and NFXVII, pp. 1960-1361, 1967-1968, 1990.
Wyandotte Chemicals Corporation, "Information on Applications of Pluronics," pp. 1-13 (Mar. 1, 1952).
Chang C. Paul
McGregor Weldon C.
Stubstad James
Sayala Chhaya D.
Xoma Corporation
LandOfFree
Pharmaceutical composition comprising BPI proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition comprising BPI proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition comprising BPI proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-156625